XMT-2175 / Mersana - LARVOL DELTA

Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones (GlobeNewswire) - "XMT-1592, a first Dolasynthen ADC targeting NaPi2b, is currently in a Phase 1 trial, with dose exploration expected to be complete in the second half of 2022....XMT-1660, a first-in-class Dolasynthen ADC targeting B7-H4, is expected to initiate a Phase 1 dose escalation trial in mid-2022....XMT-2056, a first-in-class HER2-targeted Immunosynthen STING-agonist ADC, is expected to initiate a Phase 1 dose escalation trial in mid-2022....The Company plans to disclose two new development candidates, XMT-2068 and XMT-2175, during the first half of 2022....The Company will review these corporate updates and milestones during its upcoming presentation at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 pm ET."

Clinical • New P1 trial • Trial completion date • Oncology